ecteinascidin 743
- Product Name
- ecteinascidin 743
- CAS No.
- 114899-77-3
- Chemical Name
- ecteinascidin 743
- Synonyms
- Trabectedin;ET-743;Yondelis;Ecteinascidin;NSC 648766;NSC-684766;ASMF Filed;cteinascidin;ecteinascidin 743;Trabectedin, >95%
- CBNumber
- CB31364731
- Molecular Formula
- C39H43N3O11S
- Formula Weight
- 761.84
- MOL File
- 114899-77-3.mol
ecteinascidin 743 Property
- Melting point:
- >143°C (dec.)
- alpha
- D25 +114° (c = 0.1 in methanol)
- Density
- 1.55±0.1 g/cm3 (20 ºC 760 Torr)
- storage temp.
- -20°C Freezer, Under inert atmosphere
- solubility
- Chloroform (Slightly), Methanol (Slightly)
- pka
- 9.73±0.40(Predicted)
- form
- Solid
- color
- Light Yellow to Yellow
- InChI
- InChI=1/C39H43N3O11S/c1-16-9-20-10-22-37(46)42-23-13-50-38(47)39(21-12-25(48-5)24(44)11-19(21)7-8-40-39)14-54-36(30(42)29(41(22)4)26(20)31(45)32(16)49-6)28-27(23)35-34(51-15-52-35)17(2)33(28)53-18(3)43/h9,11-12,22-23,29-30,36-37,40,44-46H,7-8,10,13-15H2,1-6H3/t22-,23-,29+,30+,36+,37-,39+/s3
- InChIKey
- PKVRCIRHQMSYJX-HAHYLZASNA-N
- SMILES
- [C@H]12[C@@H]3N([C@@H](CC4=CC(C)=C(OC)C(O)=C34)[C@H](O)N1[C@@H]1C3=C4OCOC4=C(C)C(OC(=O)C)=C3[C@@]2([H])SC[C@]2(NCCC3C=C(O)C(OC)=CC2=3)C(=O)OC1)C |&1:0,1,3,15,18,33,37,r|
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Danger
- Hazard statements
-
H300Fatal if swallowed
H312Harmful in contact with skin
H332Harmful if inhaled
H341Suspected of causing genetic defects
H361Suspected of damaging fertility or the unborn child
H373May cause damage to organs through prolonged or repeated exposure
- Precautionary statements
-
P201Obtain special instructions before use.
P202Do not handle until all safety precautions have been read and understood.
P260Do not breathe dust/fume/gas/mist/vapours/spray.
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P264Wash hands thoroughly after handling.
P264Wash skin thouroughly after handling.
P270Do not eat, drink or smoke when using this product.
P271Use only outdoors or in a well-ventilated area.
P280Wear protective gloves/protective clothing/eye protection/face protection.
P281Use personal protective equipment as required.
P301+P310IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P302+P352IF ON SKIN: wash with plenty of soap and water.
P304+P340IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P308+P313IF exposed or concerned: Get medical advice/attention.
P312Call a POISON CENTER or doctor/physician if you feel unwell.
P314Get medical advice/attention if you feel unwell.
P321Specific treatment (see … on this label).
P322Specific measures (see …on this label).
P330Rinse mouth.
P363Wash contaminated clothing before reuse.
P405Store locked up.
P501Dispose of contents/container to..…
N-Bromosuccinimide Price
- Product number
- T703500
- Product name
- Trabectedin
- Packaging
- 5mg
- Price
- $1000
- Updated
- 2021/12/16
- Product number
- T703500
- Product name
- Trabectedin
- Packaging
- 25mg
- Price
- $3500
- Updated
- 2021/12/16
- Product number
- A3886
- Product name
- Trabectedin
- Packaging
- 1mg
- Price
- $2511
- Updated
- 2021/12/16
- Product number
- API0005339
- Product name
- TRABECTEDIN
- Purity
- 95.00%
- Packaging
- 10MG
- Price
- $55440
- Updated
- 2021/12/16
- Product number
- DC10611
- Product name
- Trabectedin
- Purity
- >99%
- Packaging
- 5mg
- Price
- $1700
- Updated
- 2021/12/16
ecteinascidin 743 Chemical Properties,Usage,Production
Description
Trabectedin is a marine natural product derived from the tunicate Ecteinascidia turbinate. With its demonstrated in vitro and in vivo activity against a range of solid tumor cell lines, human xenografts and tumor explants, this antineoplastic agent has been developed and launched for the treatment of advanced STS after failure of first-line therapy with anthracyclines or ifosfamide or in patients who are unsuited to receive these agents. Its proposed mechanism of action involves binding to the N2 position of guanine in the minor groove demonstrating a preference for sequences containing 5′-PuGC and 5′-PyGG motifs. Subsequent alkylation of DNA, via an iminium intermediate generated from an intra-molecular acid-catalyzed activation and dehydration of the carbinolamine, induces a curvature of the DNA toward the major groove that ultimately disrupts the binding of transcription factors involved in cell proliferation. Evaluation of trabectedin against the National Cancer Institute’s human in vitro cell line panel, including melanoma, non-small-cell lung, ovarian, renal, prostate, and breast cancer, demonstrated potencies ranging from 1 pM to 10 nM.
Originator
University of Illinois (US)
Uses
A tetrahydroisoquinoline alkaloid with antitumor activity isolated from the Caribbean tunicate, Ecteinascidin turbinata. It is the first marine anticancer agent approved in the European Union for patients with soft tissue sarcoma (STS). Antineoplastic.
Definition
ChEBI: A tetrahydroisoquinoline alkaloid obtained from a Caribbean tunicate Ecteinascidia turbinata. Used for the treatment of soft tissue sarcoma and relapsed ovarian cancer.
brand name
Yondelis
Clinical Use
Antineoplastic agent:
Advanced soft tissue sarcoma
Ovarian cancer
Side effects
The most common adverse events included nausea, fatigue, vomiting, anorexia, neutropenia, and increases in aspartate aminotransferase and alanine aminotransferase liver enzymes. To combat the nausea and vomiting, all patients must receive 20mg of dexamethasone intravenously before the trabectedin infusion. Not only does this pretreatment have an antiemetic effect, it also appears to offer a hepatoprotective benefit. Concomitant administration of potent inhibitors and inducers of CYP3A4 should be avoided since plasma levels of this CYP3A4- metabolized drug will be affected. Trabectedin is contraindicated in patients with a known hypersensitivity to trabectedin, concurrent serious or uncontrolled infection, or breast-feeding. Trabectedin should also not be administered in combination with yellow fever vaccine. Finally, there are strict criteria regarding absolute neutrophil count, platelet count, and renal and hepatic enzyme levels for permission to initiate or continue treatment with trabectedin.
Synthesis
While the challenging total synthesis of trabectedin has been accomplished by a few research groups, the commercial preparation begins from readily available cyanosafracin B in 21 steps. Following the Boc and MOM protection of the amine and phenol functionalities, respectively, the methoxy-pquinone was hydrolyzed with sodium hydroxide in methanol. The resulting quinine was reduced (hydrogen over Pd/C) to give an unstable hydroquinone that was subsequently alkylated with bromochloromethane and allyl bromide. The MOM and Boc groups were then removed followed by cleavage of the amide by Edman degradation (through formation of the thiourea with phenyl isothiocyanate and treatment with HCl in 1,4-dioxane). At this point, the amine was protected as the TROC carbamate before reprotecting the phenol as the MOM ether and then liberating the amine with zinc in acetic acid. The amine was converted to an alcohol moiety with sodium nitrite in acetic acid, and this handle was acylated with (S)-N-[(trichloroethoxy)carbonyl]-S-(9-fluorenylmethyl)cysteine. Removal of the allyl-protecting group followed by oxidation provided an 492 Shridhar Hegde and Michelle Schmidt alpha-hydroxy ketone intermediate. Dehydration and deprotection of the cysteine established the Michael addition of the thiol to the o-quinone methide with concomitant trapping with acetic anhydride. The remaining steps involved removal of protecting groups, installation of the tetrahydroisoquinoline ring via a Pictet Spengler reaction, and conversion of the cyano to the alcohol of the carbinolamine with silver nitrate in acetonitrile and water.
Drug interactions
Potentially hazardous interactions with other drugs
Alcohol: Avoid concomitant use.
Antibacterials: concentration reduced by rifampicin.
Antipsychotics: avoid with clozapine, increased risk
of agranulocytosis.
Vaccines: risk of generalised infections - avoid.
Metabolism
Metabolised in the liver, mainly by cytochrome P450 isoenzyme CYP3A4. Excreted mainly via the faeces.
ecteinascidin 743 Preparation Products And Raw materials
Raw materials
Preparation Products
ecteinascidin 743 Suppliers
- Tel
- 021-61001086 13671938079
- Fax
- 021-61114075
- sales@wuyanpharm.com
- Country
- China
- ProdList
- 99
- Advantage
- 55
- Tel
- 15317222985
- Fax
- binbin.lin@cepharm.cn
- bingna.wang@cepharm.cn
- Country
- China
- ProdList
- 130
- Advantage
- 58
- Tel
- 021-52919136 17315815539
- 2804155403@qq.com
- Country
- China
- ProdList
- 169
- Advantage
- 58
- Tel
- 18884146872
- bd@xilinglab.com
- Country
- China
- ProdList
- 12
- Advantage
- 58
- Tel
- 021-58950125
- Fax
- 021-58955996
- info@chemexpress.com
- Country
- China
- ProdList
- 695
- Advantage
- 58
- Tel
- 18086626237 18086626237
- Fax
- qq:2693528373
- sales@debyesci.com
- Country
- China
- ProdList
- 2643
- Advantage
- 56
- Tel
- 021-50790412
- Fax
- +86-21-50790419
- info@chemvon.com
- Country
- China
- ProdList
- 371
- Advantage
- 57
- Tel
- 021-20908456
- Fax
- 021-58180499
- sales@BioChemBest.com
- Country
- China
- ProdList
- 6011
- Advantage
- 61
- Tel
- 021-021-58432009 400-005-6266
- Fax
- 021-58436166
- sales8178@energy-chemical.com
- Country
- China
- ProdList
- 44751
- Advantage
- 61
- Tel
- 1-(800)-881-8210
- Fax
- 615-250-9817
- inquiries@lgmpharma.com
- Country
- United States
- ProdList
- 2127
- Advantage
- 70
View Lastest Price from ecteinascidin 743 manufacturers
- Product
- ecteinascidin 743 114899-77-3
- Price
- US $30.00-11.00/kg
- Min. Order
- 1kg
- Purity
- 0.99
- Supply Ability
- 20 tons
- Release date
- 2023-11-23
- Product
- Trabectedin 114899-77-3
- Price
- US $0.00/MG
- Min. Order
- 1MG
- Purity
- 98%min
- Supply Ability
- 30kg/month
- Release date
- 2023-02-06
- Product
- ecteinascidin 743 114899-77-3
- Price
- US $2.00/kg
- Min. Order
- 1kg
- Purity
- 99%
- Supply Ability
- 100kg
- Release date
- 2018-12-23